Resources Repository
-
ArticlePublication 2016Using Cost-Effectiveness Evidence to Inform Health Service Provision
This article discusses three challenges of using cost-effectiveness thresholds to inform whether a third-party payer …
This article discusses three challenges of using cost-effectiveness thresholds to inform whether a third-party payer will fund a particular service. First, how is the appropriate cost-effectiveness threshold - or threshold range - to be determined? (And should there be a single threshold or multiple thresholds?) Second, how can the valuation of health benefits be refined to better capture the value of treatments to patients and to the economy as a whole? Third, how should a…
Evidence Synthesis | Priority Setting/Ethics | Health/Medicine | Cost-Effectiveness Analysis | Policy/Regulation | Global -
ArticlePublication 2015Cancer Models and Real-World Data: Better Together
Decision-analytic models synthesize available data on disease burden and intervention effectiveness to project estimates of …
Decision-analytic models synthesize available data on disease burden and intervention effectiveness to project estimates of the long-term consequences of care. While models have been influential in informing US cancer screening guidelines under ideal conditions, incorporating detailed data on real-world screening practice has been limited given the complexity of screening processes and behaviors throughout diverse health delivery systems in the United States. The authors describe the synergies that exist between decision-analytic models and health care utilization…
Evidence Synthesis | Calibration/Validation | Health/Medicine | Mathematical Models | Chronic Disease/Risk | Health Systems | Clinical Care | Science/Technology | North America -
ArticlePublication 2015A Conceptual Model for Breast, Cervical, and Colorectal Cancer Screening
General frameworks of the cancer screening process are available, but none directly compare the process …
General frameworks of the cancer screening process are available, but none directly compare the process in detail across different organ sites. This limits the ability of medical and public health professionals to develop and evaluate coordinated screening programs that apply resources and population management strategies available for one cancer site to other sites. This paper presents a conceptual model that incorporates a single screening episode for breast, cervical, and colorectal cancers into a unified framework based…
Evidence Synthesis | Preferences/Values | Health/Medicine | Health Outcomes | Test Performance | Microsimulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Clinical Care | Science/Technology | North America -
ArticlePublication 2015Population Health Model (POHEM): An Overview
This paper provides an overview of the rationale, methodology and applications of the Population Health …
This paper provides an overview of the rationale, methodology and applications of the Population Health Model (POHEM). POHEM is a health microsimulation model, developed at Statistics Canada in the early 1990s. The authors describe that POHEM draws together rich multivariate data from a wide range of sources to simulate the lifecycle of the Canadian population, specifically focusing on aspects of health. The model dynamically simulates individuals’ disease states, risk factors, and health determinants, in order…
Evidence Synthesis | Calibration/Validation | Health/Medicine | Costing Methods | Mathematical Models | Microsimulation | Chronic Disease/Risk | Health Systems | Policy/Regulation | Clinical Care | Economics/Finance | North America -
ArticlePublication 2015Extended Cost-Effectiveness Analysis of Treatment and Prevention of Diarrhoea in Ethiopia
This article, published in BMJ Open, aims to illustrate the size and distribution of benefits …
This article, published in BMJ Open, aims to illustrate the size and distribution of benefits due to the treatment and prevention of diarrhoea (i.e., rotavirus vaccination) in Ethiopia. The authors use an economic model to examine the impacts of universal public finance (UPF) of diarrhoeal treatment alone, as opposed to diarrhoeal treatment along with rotavirus vaccination using extended cost-effectiveness analysis (ECEA). The study finds that diarrhoeal treatment paired with rotavirus vaccination is more cost effective…
Priority Setting/Ethics | Health/Medicine | Climate/Environment | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Infectious Diseases | Child/Nutrition | Social Determinants | Environmental Health | Health Systems | Economics/Finance | Sub-Saharan Africa -
ArticlePublication 2023Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK & the U.S.
This study aimed to create UK and US EQ-5D-3L-based health-related quality of life (HRQoL) utility …
This study aimed to create UK and US EQ-5D-3L-based health-related quality of life (HRQoL) utility population catalogues for 199 chronic conditions using ICD-10 codes and health risks. It also sought to develop regression models to predict these utilities in other populations. Methods involved applying UK and US EQ-5D-3L value sets to responses from a Danish dataset, which combined national health survey data with national registers containing patient information on diagnoses, healthcare activities, and socio-demographics. Adjusted…
Preferences/Values | Health/Medicine | Health Outcomes | North America | Europe -
ArticlePublication 2023Alternative Measure of Health for Value Assessment: Equal Value Life-Year
This study examines the equal value life-year (evLY) as an alternative or complementary measure to …
This study examines the equal value life-year (evLY) as an alternative or complementary measure to the quality-adjusted life-year (QALY) in cost-effectiveness analyses. The QALY is criticized for undervaluing treatments that extend the life of individuals with chronic disabilities. The evLY addresses this by assigning equal value to life-years, regardless of health status. Methods included presenting the conceptual rationale for the evLY, explaining its estimation, and comparing results from evLY-based analyses to QALY-based analyses. The study…
Preferences/Values | Health/Medicine | Health Outcomes | Cost-Effectiveness Analysis -
ArticlePublication 2023Developing Criteria for Health Economic Quality Evaluation Tool
This study presents the development of a novel quality assessment tool for cost-effectiveness analyses (CEAs) …
This study presents the development of a novel quality assessment tool for cost-effectiveness analyses (CEAs) named the Criteria for Health Economic Quality Evaluation (CHEQUE). The tool introduces three major enhancements: differentiating methods and reporting quality, quantifying the relative importance of different quality attributes, and providing an accessible, web-based tool for usability. Methods involved defining 15 quality domains and identifying 72 quality attributes through a scoping review. Researchers and practitioners were surveyed using a best-worst scaling…
Evidence Synthesis | Health/Medicine | Cost-Effectiveness Analysis -
ArticlePublication 2023Evaluation of Diversity of Clinical Trials Informing Health Technology Assessments in the United States: A 5-Year Analysis of Institute for Clinical and Economic Review Assessments
The study assessed the diversity of clinical trials informing assessments by the Institute for Clinical …
The study assessed the diversity of clinical trials informing assessments by the Institute for Clinical and Economic Review (ICER) over five years (2017-2021). It conducted a cross-sectional analysis of 208 pivotal trials across 31 conditions. Findings revealed inadequate representation of racial/ethnic minorities and older adults, with Blacks/African Americans, American Indians/Alaska Natives, and Hispanics/Latinos being notably underrepresented. Whites, Asians, and Native Hawaiian/Other Pacific Islanders were adequately represented. US-based trials better represented Blacks/African Americans and Hispanics/Latinos but…
Evidence Synthesis | Health/Medicine | Technology Assessment | North America